Noxopharm Ltd (ASX:NOX) CEO and managing director Dr Graham Kelly speaks to Proactive's Andrew Scott after reporting positive interim data from its NOXCOVID trial. The interim data points to Veyonda in a cohort of 18 patients with moderately severe COVID19 disease, providing protection against progression of severe inflammation associated with a worsening of the disease.
Noxopharm CEO encouraged by positive interim data from NOXCOVID trial
